A5006577120- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Helicobacter pylori-related gastroenterology studies
- Pancreatic and Hepatic Oncology Research
- Esophageal and GI Pathology
- Cancer, Hypoxia, and Metabolism
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Cancer Mechanisms and Therapy
- Cancer therapeutics and mechanisms
- Palliative Care and End-of-Life Issues
- Patient Dignity and Privacy
- Sarcoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Liver Disease Diagnosis and Treatment
- Renal cell carcinoma treatment
Asan Medical Center
2016-2025
University of Ulsan
2016-2025
Ulsan College
2016-2025
Seoul Medical Center
2022-2023
National Cancer Center
2009-2021
National Cancer Institute
2012-2021
GTx (United States)
2017
Breast Cancer Research Foundation
2014
Center for Cancer Research
2013
National Institutes of Health
2013
Purpose The Avastin in Gastric Cancer (AVAGAST) trial was a multinational, randomized, placebo-controlled designed to evaluate the efficacy of adding bevacizumab capecitabine-cisplatin first-line treatment advanced gastric cancer. Patients and Methods received 7.5 mg/kg or placebo followed by cisplatin 80 mg/m 2 on day 1 plus capecitabine 1,000 twice daily for 14 days every 3 weeks. Fluorouracil permitted patients unable take oral medications. Cisplatin given six cycles; were administered...
Atezolizumab-bevacizumab is the new standard of care for first-line treatment advanced hepatocellular carcinoma (HCC). However, optimal sequence therapy after disease progression on atezolizumab-bevacizumab unclear.This multinational, multicenter, and retrospective study assessed clinical outcomes patients with HCC who received subsequent systemic between July 2016 April 2019.Among 71 treated atezolizumab-bevacizumab, a total 49 were included in this analysis; median age was 60 years (range,...
Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. We conducted an Asian multinational phase II study for patients gastric ≥10 cm. Patients received neoadjuvant (400 mg/day) 6–9 months. The primary end point was R0 resection rate. A total of 56 were enroled in this study. In full analysis set 53 patients, ≥6 months...
Abstract BACKGROUND. The objective of the current study was to assess staging accuracy and prognostic role preoperative endoscopic ultrasound (EUS) computed tomography (CT) in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy. METHODS. Presurgical LAGC underwent EUS CT before 3 cycles Chemotherapy comprised docetaxel (at a dose 36 mg/m 2 ) cisplatin 40 on Days 1 8 3‐week cycle. RESULTS. Forty were enrolled study. After chemotherapy, found be 47% 57%,...
Although sorafenib is the global standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC), it does not have reliable predictive or prognostic biomarkers. Circulating cell-free DNA (cfDNA) has shown promise as a biomarker various cancers. We investigated use of cfDNA to predict clinical outcomes in HCC patients treated with sorafenib. This prospective study analyzed plasma from 151 who received and 14 healthy controls. The concentration VEGFA-to-EIF2C1 ratios...
Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) previous trials. However, real-world data of nivolumab HCC patients, especially those Child-Pugh class B, are limited. To investigate the effectiveness a cohort advanced HCC, we retrospectively evaluated 203 who were treated between July 2017 February 2019. Of 132 classified as A 71 B. Objective rate was lower B than (2.8% vs. 15.9%; p = 0.010). an independent negative predictor for objective...
Abstract Multi-cancer early detection remains a key challenge in cell-free DNA (cfDNA)-based liquid biopsy. Here, we perform cfDNA whole-genome sequencing to generate two test datasets covering 2125 patient samples of 9 cancer types and 1241 normal control samples, also reference dataset for background variant filtering based on 20,529 low-depth healthy samples. An external consisting 208 214 is used additional evaluation. Accuracy tissue-of-origin localization achieved using our algorithm,...
Purpose We conducted this study to evaluate the validity of perception that awareness their terminal prognosis and use palliative care or nonuse an intensive unit (ICU) causes patients die sooner than they would otherwise. Patients Methods In prospective cohort at 11 university hospitals National Cancer Center in Korea, we administered questionnaires 619 consecutive immediately after were determined by physicians be terminally ill. followed during 6 months enrollment assessed how survival...
In Brief Background: the era of pre- or perioperative therapy for gastric cancer, clinical staging before treatment appears to be increasingly important prognosis, yet there are no data on subject resectable cancer patients. Objectives: To evaluate prognostic role preoperative locoregional in patients undergoing curative resection. Methods: We reviewed 1964 who underwent resection without from 2001 2005. performed computed tomography and according both International Union Against Cancer...
Family history of gastric cancer is a major risk factor for the disease. In this study, we investigated prognoses patients with family history.We retrospectively reviewed data from 1,273 adenocarcinoma who had undergone gastrectomy between 2001 and 2005 at tertiary center hospital. A positive was defined as self-reported in first- or second-degree relatives. Patients were followed up until December 2009 death recurrence. Clinicopathologic characteristics compared by history. Kaplan-Meier...